AMPA receptor antagonist. Non-selective homomeric GluR3 and GluR1 receptor antagonist (IC50 values are 263 and 296 nM respectively). Inhibits homomeric GluR3 and GluR1 with a 100-fold greater potency than heteromeric GluR1/2 and GluR2/3 receptors.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 507.54. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.97 mL||9.85 mL||19.7 mL|
|5 mM||0.39 mL||1.97 mL||3.94 mL|
|10 mM||0.2 mL||0.99 mL||1.97 mL|
|50 mM||0.04 mL||0.2 mL||0.39 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Nilsen and England (2007) A subtype-selective, use-dependent inhibitor of native AMPA receptors. J.Am.Chem.Soc. 129 4902 PMID: 17391037
Poulsen et al (2013) Evaluation of PhTX-74 as subtype-selective inhibitor of GluA2-containing AMPA receptors. Mol.Pharmacol. 85 261 PMID: 24220009
If you know of a relevant reference for Philanthotoxin 74, please let us know.
View Related Products by Product Action
Keywords: GluR1/2 selective AMPA antagonists Glutamate Receptors iGluR Ionotropic Philanthotoxin74 PhTx74 homomeric GluR3 GluR1 GluR2/3 PhTx-74 AMPA Receptors
1 Citation for Philanthotoxin 74
Citations are publications that use Tocris products. Selected citations for Philanthotoxin 74 include:
Kim and Ziff (2014) Calcineurin mediates synaptic scaling via synaptic trafficking of Ca2+-permeable AMPA receptors. PLoS Biol 12 e1001900 PMID: 24983627
Do you know of a great paper that uses Philanthotoxin 74 from Tocris? If so please let us know.
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.